In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.
"The last two years have been very challenging for the company, but as a result of recent progress, I believe we are solidly on a turnaround path and well on our way to building significant shareholder value," stated
Nucleic acids are extremely promising for the treatment of complex and orphan diseases, yet efficient and cell-specific delivery of oligonucleotide therapeutics remains a barrier to clinical progress. Furthermore, as many illnesses are multi-system diseases (i.e., they affect more than one organ or physiological process), treatment will likely not be successful using a singular therapeutic or delivery regimen. Successful treatment may require a customizable approach over the course of care that employs multiple therapeutics, each with a unique biological target, dose, and delivery mechanism. The ability to develop both single- and double-stranded oligonucleotide constructs and combine them with a breadth of delivery technologies will likely provide the greatest chance for clinical success.
Most Popular Stories
- IBM to Pay Big to Unload Chip Division
- Paniagua Wins Grand Prize in Young Artists Program
- Sub Hunt Brings Cold War Chill Back to Baltic
- Canadian Pacific Ends CSX Talks
- US Stocks Move Higher Despite Drag by IBM
- Cowboys Turn Back Clock to Glory Days
- Kerry Cites Moral Need in Weapons Air Drop
- Yaris Adds French Flair for US Market
- Peyton Manning Sets TD Passing Record
- Early Voting Begins in Texas